Abstract
Tumor immune escape variants can be identified in human and experimental tumors. A variety of different strategies are used by tumor cells to avoid recognition by different immune effector mechanisms. Among these escape routes, alteration of MHC class I cell surface expression is one of the mechanisms most widely used by tumor cells. In this review we focus our attention on the T-cell immune selection of MHC class I–deficient tumor variants. Different altered MHC class I phenotypes that originate from multiple molecular mechanisms can be identified in human tumors. MHC-deficient tumor clones can escape T-cell immune responses, but are in theory more susceptible to NK-cell–mediated lysis. In this context, we also review the controversial issue of the aberrant expression of nonclassical HLA class I molecules, particularly HLA-G, in tumors. This expression may be relevant in tumor cells that have lost the capacity to interact with NK inhibitory receptors—namely, those tumor cells with no HLA-B or HLA-C expression. Most published studies have not analyzed these possibilities and do not provide information about the complete HLA-A, HLA-B, or HLA-C molecule profiles of the tumors studied. In contrast, HLA-E has been reported to be expressed in some tumor cell lines with very low HLA-A, HLA-B, and HLA-C expression, suggesting that HLA-E may indeed, in some cases, play a role by inhibiting NK lysis of cells that otherwise would be destroyed by NK cells. Finally, we provide evidence that the status of the immune system in the tumor-bearing animal is capable of defining the MHC profile of the tumor cells. In other words, MHC class I–negative metastatic colonies are produced in immunocompetent animals, and MHC class I–positive colonies in T-cell immunodeficient individuals.
Similar content being viewed by others
References
Ahmed I, Hamacher KL (2002) Angiosarcoma in a chronically immunosuppressed renal transplant recipient: report of a case and review of the literature. Am J Dermatopathol 24:330
Algarra I, Gaforio JJ, Garrido A, Mialdea MJ, Pérez M, Garrido F (1991) Heterogeneity of MHC-class I antigens in clones of methylcholanthrene induced tumors: implications for local growth and metastasis. Int J Cancer 6:73
Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727
Boesen M, Svane IM, Engel M, Rygaard J, Thomsen AR, Werdelin O (2000) CD8+ T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3-methylcholanthrene. Clin Exp Immunol 121:1365
Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337
Botti C, Seregni E, Ferrari L, Martinetti A, Bombardieri E (1998) Immunosuppressive factors: role in cancer development and progression. Int J Biol Markers 13:51
Braud V, Jones EY, McMichael A (1997) The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol 27:1164
Bukur J, Seliger B (2003) The role of HLA G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies. Sem Cancer Biol 13:353
Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1
Cadranel J, Naccache J, Wislez M, Mayaud C (1999) Pulmonary malignancies in the immunocompromised patient. Respiration 66:289
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991
Ehrlich P (1909) Ueber den jetzigen Stand der Karzinomforschung (About the current state of the art of cancer research). NedTijdschr Geneesk 5:273
Engel AM, Svane IM, Rigaard J, Werdelin O (1997) MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 45:463
Frumento G, Franchello S, Palmisano GL, Nicotra MR, Giacomini P, Loke YW, Geraghty DE, Maio M, Manzo C, Natali PG, Ferrara GB (2000) Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gamma-IFN treatment. Tissue Antigens 56:30
Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z (2003) Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 198:433
Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I deficient metastatic tumor variants. Int J Cancer 91:109
Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106:521
Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance and tumor immune escape. J Cell Physiol 195:346
Garrido A, Pérez M, Delgado C, Garrido ML, Rojano J, Algarra I, Garrido F (1986) Influence of class I H-2 gene expression on local tumor growth. Exp Clin Immunogenet 13:98
Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117
Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491
Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern P (1997) Implications for immune surveillance of altered HLA class I phenotypes in human tumors. Immunol Today 18:89
Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC (2001) Regulation of cutaneous malignancy by gammadelta T cells. Science 294:605
Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, Tigelaar RE, Hayday AC (2003) The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med 198:747
Groh V, Steinle A, Bauer S, Spies T (1998) Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279:1737
Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T (2001) Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2:255
Haliotis T, Ball JK, Dexter D, Roder JC (1985) Spontaneous and induced primary oncogenesis in natural killer (NK)-cell deficient beige mutant mice. Int J Cancer 35:505
Hayashi T, Faustman DL(2002) Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res 62:24
Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth (1996) A Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66:470
Johnsen A, Templeton DJ, Sy MS, Harding CV (1999) Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 163:4224
Kagi DB, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H (1994) Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31
Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an interferon gamma dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95:7556
Le Bouteiller P (1997) HLA-G: on the track of immunological functions. Eur J Immunogenet 24:397
Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340
Llano M, Lee N, Navarro F, Garcia P, Albar JP, Geraghty DE, Lopez-Botet M (1998) HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 28:2854
Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, Garrido F (2003) Analysis of HLA-E expression in human tumors. Immunogenetics 54:767
McClain KL (1997) Immunodeficiency states and related malignancies. Cancer Treat Rev 92:39
Mendez R, Serrano A, Jager E, Maleno I, Ruiz Cabello F, Knuth A, Garrido F (2001) Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens 57:508
Meyer T, Arndt R, Nindl I, Ulrich C, Christophers E, Stockfleth E (2003) Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients. Transpl Int 16:146
Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L (1996) Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14:619
Nemes B, Zalatnai A, Podder H, Jaray J, Sotonyi P Jr, Schaff Z, Foldes K, Perner F (2000) Papillary microcarcinoma of the thyroid gland in renal transplant patients. Pathol Oncol Res 6:72
Otley CC, Pittelkow MR (2000) Skin cancer in liver transplant recipients. Liver Transpl 6:253
Pangault C, Amiot L, Caulet-Maugendre S, Brasseur F, Burtin F, Guilloux V, Drenou B, Fauchet R, Onno M (1999) HLA-G protein expression is not induced during malignant transformation. Tissue Antigens. 53:335
Pardoll DM (2003) Does the immune system see tumors as foreign or self? Annual Rev Immunol 21:807
Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED (1998) HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 95:4510
Pérez M, Algarra I, Ljunggren HG, Caballero A, Mialdea MJ, Gaforio JJ, Garrido F (1990) A weakly tumorigenic phenotype with high MHC class I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma. Int J Cancer 46:258
Prehn RT, Main JM (1957) Immunity to methylcholanthrene induced sarcomas. J Natl Cancer Inst 18:769
Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F (1999) Expression of HLA G in human tumors is not a frequent event. Int J Cancer 81:512
Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3
Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman D, Theoret MR, Touloukian CE (2002) Assumptions of the tumor ‘escape’ hypothesis. Sem Cancer Biol 12:81
Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Sem Cancer Biol 12:3
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Scheriber RD (2001) IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 26:1107
Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA (2000) Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 192:755
Smyth MJ, Crowe NY, Godfrey DI (2001) NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13:459
Stern PL (1996) Immunity to human papillomavirus associated cervical neoplasia. Adv Cancer Res 69:175
Street SE, Cretney E, Smyth MJ (2001) Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97:192
Stutman O (1979) Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst 62:353
Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O (1996) Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 26:1844
Thomas L (1959) Discussion of cellular and humoral aspects of the hypersensitivity states. In: Lawrence HS (ed) Cellular and humoral aspects of the hypersensitive states. Hoeber-Harper, New York, p 529
Tomasec P, Braud V, Rickards C, Powell M, McSharry B, Gadola S, Cerundolo V, Borysiewicz L, McMichael A, Wilkinson G (2000) Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287:1031
Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 28:959
van den Broek MF, Kagi D, Zinkernagel RM, Hengartner H (1995) Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol 25:3514
Van den Eynde BJ, Van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684
Winter P, Schoeneich G, Miersch WD, Klehr HU (1997) Tumour induction as a consequence of immunosuppression after renal transplantation. Int Urol Nephrol 29:701
Yokota J (2000) Tumour progression and metastasis. Carcinogenesis 21:497
Acknowledgements
This work was supported in part by the Fondo de Investigaciones Sanitarias, Plan Nacional de Investigacion, through Project no. BSA 2001/3080, and by the Plan Andaluz de Investigacion. We thank K. Shashok for improving the English in the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article forms part of the Symposium in Writing “Tumor escape from the immune response,” published in Vol. 53.
Rights and permissions
About this article
Cite this article
Algarra, I., García-Lora, A., Cabrera, T. et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53, 904–910 (2004). https://doi.org/10.1007/s00262-004-0517-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-004-0517-9